BioNTech (NASDAQ:BNTX) CEO Sells $3,347,980.00 in Stock

Posted by Brian Himes on Oct 1st, 2026

BioNTech SE Sponsored ADR (NASDAQ:BNTX – Get Free Report) CEO Ugur Sahin sold 34,000 shares of the stock in a transaction on Monday, September 28th. The shares were sold at an average price of $98.47, for a total value of $3,347,980.00. Following the sale, the chief executive officer owned 246,209 shares of the company’s stock, valued at $24,244,200.23. This trade represents a 12.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total value of $3,139,840.00.
On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $98.69, for a total transaction of $2,664,630.00.
On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total value of $3,860,610.00.
On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total transaction of $2,982,000.00.
On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total transaction of $4,633,120.00.
On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total transaction of $3,227,730.00.
On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total transaction of $2,886,600.00.
On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total transaction of $3,352,400.00.
On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00.
On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total transaction of $3,280,660.00.

BioNTech Stock Performance

BNTX opened at $98.30 on Thursday. The stock has a 50-day moving average of $98.56 and a 200-day moving average of $94.96. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. BioNTech SE Sponsored ADR has a 52-week low of $79.52 and a 52-week high of $124.00. The company has a market cap of $24.86 billion, a PE ratio of -12.55 and a beta of 1.29.

BioNTech (NASDAQ:BNTX – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. During the same quarter in the previous year, the company earned ($1.60) EPS. BioNTech’s revenue for the quarter was down 59.5% compared to the same quarter last year. As a group, equities research analysts forecast that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on BNTX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. Wall Street Zen cut shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Berenberg Bank set a $140.00 price objective on shares of BioNTech in a research report on Wednesday, September 16th. Citigroup dropped their price objective on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. Finally, Morgan Stanley decreased their price target on BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and an average target price of $126.00.

Get Our Latest Stock Analysis on BioNTech

Institutional Investors Weigh In On BioNTech

Large investors have recently modified their holdings of the stock. Flossbach Von Storch SE purchased a new position in shares of BioNTech in the second quarter worth $207,142,000. BNP Paribas Financial Markets lifted its stake in BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after purchasing an additional 474,796 shares during the last quarter. Bank of America Corp DE boosted its holdings in BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after purchasing an additional 166,432 shares during the period. First Trust Advisors LP increased its stake in BioNTech by 116.0% during the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock valued at $74,658,000 after purchasing an additional 451,124 shares during the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in BioNTech during the second quarter valued at $39,385,000. 15.52% of the stock is owned by institutional investors.

About BioNTech

(Get Free Report)

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.